- \n
- Why early material strategy defines clinical success<\/li>\n\n\n\n
- Understanding raw and ancillary materials in cell therapy<\/li>\n\n\n\n
- Regulatory landscape and GMP expectations<\/li>\n\n\n\n
- Defining GMP-grade and supplier qualification<\/li>\n\n\n\n
- Assessing critical raw material attributes<\/li>\n\n\n\n
- Documentation and traceability essentials<\/li>\n\n\n\n
- Regulatory Support Files and collaboration<\/li>\n\n\n\n
- Case Studies<\/li>\n\n\n\n
- Summary: Building a long-term raw material strategy<\/li>\n<\/ul>\n\n\n\n
For the full story,<\/p>\n\n\n\n
<\/div>\n\n\n\n\nRead our Cell Therapy Handbook<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nWhy early material strategy defines clinical success<\/strong><\/h2>\n\n\n\n
Successful clinical translation of a cell therapy product depends on early decisions about both the process design and the raw materials that support it. The materials selected during process development directly influence manufacturing efficiency, scalability, safety, and eventual regulatory approval. If raw materials fail to meet clinical- or commercial-grade standards, substitutions later in development can lead to costly comparability testing, revalidation, and regulatory delays.<\/p>\n\n\n\n
An intentional strategy that emphasizes the use of GMP-grade raw materials<\/strong> or materials manufactured under robust quality management systems<\/strong> from the outset helps reduce these risks. This proactive approach supports regulatory compliance, improves consistency, and increases the probability of successful translation from bench to bedside. In a later section below, we will learn more about real-world examples of intentional strategies where early decisions helped ensure risk mitigation.<\/p>\n\n\n\n
<\/div>\n\n\n\n\nRead Case Studies<\/strong><\/a><\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nUnderstanding raw and ancillary materials in cell therapy<\/strong><\/h2>\n\n\n\n
Raw materials, also referred to as ancillary or auxiliary materials,are substances that contact the therapeutic product during manufacturing but are not intended to remain in the final drug product. These include cell culture media<\/a>, <\/strong>cytokines<\/strong><\/a>, enzymes, <\/strong>buffers<\/strong><\/a>, excipients, and cryoprotectants<\/strong>. Although they are removed from the final formulation, their specifications can profoundly affect the purity, potency, and safety of the final cell therapy. Table below lists the key considerations for raw material risk assessment.<\/p>\n\n\n\n
![\"Image](\"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/02\/image.png\")
Table 1.<\/strong> Key considerations for raw material assessment<\/figcaption><\/figure>\n\n\n\n Global regulatory bodies such as the FDA, EMA, and WHO have adopted complementary definitions for these materials, with frameworks like USP <1043><\/strong>, Ph. Eur. 5.2.12<\/strong>, and ISO 20399<\/strong> emphasizing risk-based qualification.<\/p>\n\n\n\n
One of the most globally recognized raw material guidance documents, USP <1043>, provides a framework for classifying raw materials into four different tiers based on associated risks (Figure 1).<\/p>\n\n\n\n\n\n
These guidelines converge on the expectation that therapeutic developers use the highest-grade materials feasible\u2014preferably Tier 1 or Tier 2 risk categories<\/strong> per USP <1043> \u2014 and avoid Research Use Only (RUO)<\/strong> materials for long-term processes.<\/p>\n\n\n\n
To learn more about our Gibco\u2122 Cell Therapy Systems\u2122 (CTS\u2122) media and reagents<\/p>\n\n\n\n
![\"GMP](\"https:\/\/admin.acceleratingscience.com\/behindthebench\/wp-content\/uploads\/sites\/9\/2026\/02\/Chapter-1-CTx-HB-BKG-1-1024x683.jpg\")